While the current alternative to standard therapy, i.e. mycophenolate mofetil, still needs to be confirmed with well designed, properly powered studies, new therapeutic agents, targeted to the pathogenetic mechanism of the disease, are promising improved efficacy with less toxicity.
Ayodeji Adegunsoye, Justin M. Oldham, Evans R. Fernández Pérez, Michael R Hamblin, Nina Patel, Mitchell Tener, Deepa Bhanot, Lacey B. Robinson, Sam Bullick, Lena W. Chen, Scully Hsu, Matthew M. Churpek, Donald Hedeker, Steven M. Montner, Jonathan H. Chung, Aliya N. Husain, Imre Noth, Mary E. Strek, Rekha Vij
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.